Compare General Dynamics Corporation (GD) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Dynamics Corporation vs Johnson & Johnson — how do they compare? General Dynamics Corporation trades at $365.8 (market cap $98.88B), while Johnson & Johnson trades at $250.9 (market cap $594.63B). The key difference: Johnson & Johnson is far larger — about 6× General Dynamics Corporation's market cap, and Johnson & Johnson pays the higher dividend (2.17%). Which is the better fit depends on your goals.
| GD | JNJ | |
|---|---|---|
Market Cap | $98.88B | $594.63B |
Sector | Industrials | Health |
52-Week High | $376.88 | $267.24 |
52-Week Low | $297.05 | $162.98 |
Enterprise Value | $105.06B | $627.57B |
Dividend Yield | 1.74% | 2.17% |
Volume | — | 6,156,228 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Dynamics (GD) trades at $366.40, down 0.84% on the day, with strong technical momentum indicated by bullish moving averages and oscillators. The company demonstrates solid fundamentals with Q1 2026 EPS beating expectations at $4.10 versus $3.67, continuing a trend of earnings outperformance. Revenue growth has been consistent, reaching $52.55 billion in 2025 with an 8.07% net income margin. Analyst sentiment remains positive with a $395.83 consensus price target and 53% buy ratings.
The outlook for GD is favorable given strong defense spending tailwinds and a growing $130.8 billion backlog, particularly in marine systems. However, risks include execution challenges on large contracts and potential defense budget volatility. The stock's current valuation at 23x P/E appears reasonable relative to earnings growth prospects, positioning it as a core defense holding for long-term investors.
Johnson & Johnson (JNJ) trades at $249.42, down 1.75% over 24 hours, with a bullish technical signal from moving averages but bearish oscillators. The company reported Q2 2026 EPS of $2.90, beating estimates, and raised full-year guidance. Revenue grew 6.6% annually, supported by strong pharmaceutical sales. Analyst consensus is bullish with a $281 price target, and the stock offers a stable dividend with recent payouts of $1.34 per share.
Outlook remains positive due to robust fundamentals, innovation in medtech and pharmaceuticals, and dividend king status. Risks include patent expirations, regulatory pressures, and macroeconomic volatility. The current valuation at P/E 28.66 may limit near-term upside, but long-term growth prospects appear solid.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Dynamics Corporation
General Dynamics is a defense contractor and business jet manufacturer. The firm's segments include aerospace, combat systems, marine, and technologies. The company's aerospace segment creates Gulfstream business jets. Combat system produces land-based combat vehicles, such as the M1 Abrams tank. The marine subsegment creates nuclear-powered submarines, among other things. The technologies segment contains two main units, an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computers, intelligence, surveillance, and reconnaissance capabilities to the military.
Read more on GD →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
